FDA Collects Data on Nonprescription Drug Timelines
Published Date: 6/26/2026
Notice
Summary
The FDA wants your thoughts on how they collect info about nonprescription drug applications, especially about timing and usage. This affects drug makers and anyone interested in over-the-counter meds. You’ve got until August 25, 2026, to share your comments—no fees, just your voice helping shape the process!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
OTC Time-and-Extent Applications Ending
If you make or sponsor over-the-counter (OTC) drug products, the FDA says it anticipates no submissions under 21 CFR 330.14 and plans to withdraw the TEA regulations and discontinue the related guidance. When FDA takes those actions it will also request discontinuation of the information collection approved under OMB control number 0910-0688; the notice lists an estimated burden of 861.78 hours per response and a total of 1,112 hours (placeholder) for the collection. The CARES Act added section 505G (21 U.S.C. 355h) on March 27, 2020, and comments on this collection are due by August 25, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12899 — Medical Devices; General Hospital and Personal Use Devices; Classification of the Foam or Gel Chemical Sterilant/High Level Disinfectant
The FDA is officially putting foam or gel chemical sterilants and high-level disinfectants into Class II, meaning they’ll have special safety rules but fewer red tape hurdles. This change helps companies bring safer, innovative cleaning products to hospitals and homes faster, starting June 26, 2026. If you make or use these devices, expect smoother approvals and better access without extra costs or delays.
2026-12959 — Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that the 5 mg prednisolone tablet wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of this medicine, as long as they follow the rules. Patients and pharmacies can expect continued access to affordable generics without any interruptions or extra costs.
2026-12937 — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
The FDA is giving folks more time to share their thoughts on whether certain medicines like semaglutide, tirzepatide, and liraglutide should be allowed for special compounding by outsourcing drug makers. This extension means anyone interested has until July 30, 2026, to weigh in. It affects drug makers, healthcare pros, and patients waiting for these meds, with no immediate cost changes but plenty of chances to influence future drug availability.
2026-12906 — Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.
2026-12933 — Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
The FDA is giving itself 90 more days—until September 24, 2026—to finish reviewing important feedback about certain estrogen-androgen combo drugs like Syntest tablets. This means the final decisions about these drugs’ approval are on hold a bit longer, affecting drug makers and patients waiting for updates. No extra costs are mentioned, just more time to get it right!
2026-12900 — Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
The FDA is officially putting the test that predicts preeclampsia risk into a safer, easier-to-get category called Class II. This change helps make sure the test works well and is safe, while also making it simpler for patients to access this important health tool. The new rules took effect on June 26, 2026, but the classification has been in place since May 18, 2023, helping companies save time and money on approvals.
Previous / Next Documents
Previous: 2026-12883 — Solicitation for Public Comments on the Development of an Independent Accreditation System for Certified Community Behavioral Health Clinic Expansion (CCBHC-E) Grant Recipients
SAMHSA wants your thoughts on creating an independent accreditation system for clinics that get CCBHC-E grants, which help community mental health services grow. This new system will make sure clinics meet quality standards, cut down on paperwork, and offer consistent support nationwide. Comments are open until July 27, 2026, and funding will help clinics cover accreditation costs.
Next: 2026-12885 — Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Statement of Financial Interests for Regional Fishery Management Councils
NOAA is asking to keep collecting financial info from people who want to join Regional Fishery Management Councils. This helps make sure council members follow the rules and represent their states or tribes properly. About 330 folks spend around 45 minutes each year filling out the form, and the public has 30 more days to share their thoughts.